A citation-based method for searching scientific literature

Ray Meng See, Yao Neng Teo, Yao Hao Teo, Nicholas L Syn, Alicia Swee Yan Yip, Shariel Leong, Caitlin Fern Wee, Alex Jia Yang Cheong, Chi-Hang Lee, Mark Yan-Yee Chan, Tiong Cheng Yeo, Raymond C C Wong, Peter Chang, Choon Chiet Hong, Ping Chai, Ching-Hui Sia. Pharmacology 2022
Times Cited: 3







List of co-cited articles
24 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
Tamique Mason, Otavio R Coelho-Filho, Subodh Verma, Biswajit Chowdhury, Fei Zuo, Adrian Quan, Kevin E Thorpe, Christopher Bonneau, Hwee Teoh, Richard E Gilbert,[...]. JACC Cardiovasc Imaging 2021
31
66

Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin, Michael W Fong,[...]. Diabetes Obes Metab 2021
10
66

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill,[...]. Diabetes Care 2018
268
66

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Mariam Elmegaard Malik, Emil Loldrup Fosbøl,[...]. Lancet Diabetes Endocrinol 2021
51
66

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
708
66

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Paul K Whelton, Robert M Carey, Wilbert S Aronow, Donald E Casey, Karen J Collins, Cheryl Dennison Himmelfarb, Sondra M DePalma, Samuel Gidding, Kenneth A Jamerson, Daniel W Jones,[...]. Hypertension 2018
66

Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects.
Hiddo J L Heerspink, Mehul Desai, Meg Jardine, Dainius Balis, Gary Meininger, Vlado Perkovic. J Am Soc Nephrol 2017
215
66

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Mark C Petrie, Subodh Verma, Kieran F Docherty, Silvio E Inzucchi, Inder Anand, Jan Belohlávek, Michael Böhm, Chern-En Chiang, Vijay K Chopra, Rudolf A de Boer,[...]. JAMA 2020
208
66

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
66

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
W Timothy Garvey, Luc Van Gaal, Lawrence A Leiter, Ujjwala Vijapurkar, James List, Robert Cuddihy, Jimmy Ren, Michael J Davies. Metabolism 2018
123
66

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
66

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon, Stephen D Wiviott, Avivit Cahn, Aliza Rozenberg, Ilan Yanuv, Erica L Goodrich, Sabina A Murphy, Hiddo J L Heerspink, Thomas A Zelniker, Jamie P Dwyer,[...]. Lancet Diabetes Endocrinol 2019
336
66

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
246
66

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
66

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
66


Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito, Tsutomu Hirano. Cardiovasc Diabetol 2017
92
66

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
66

Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
James L Januzzi, Jialin Xu, JingWei Li, Wayne Shaw, Richard Oh, Michael Pfeifer, Javed Butler, Naveed Sattar, Kenneth W Mahaffey, Bruce Neal,[...]. J Am Coll Cardiol 2020
32
66


Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
66

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
66

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
66

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Karin Rådholm, Gemma Figtree, Vlado Perkovic, Scott D Solomon, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Terrance D Barrett, Wayne Shaw, Mehul Desai,[...]. Circulation 2018
271
66

The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
Clare Arnott, Yuli Huang, Brendon L Neuen, Gian Luca Di Tanna, Christopher P Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic,[...]. Diabetes Obes Metab 2020
15
33

Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease.
Usama Abdel Azim Sharaf El Din, Mona Mansour Salem, Dina Ossama Abdulazim. Nefrologia (Engl Ed) 2021
2
50

Disruption of energy utilization in diabetic cardiomyopathy; a mini review.
Shinsuke Nirengi, Carmem Peres Valgas da Silva, Kristin I Stanford. Curr Opin Pharmacol 2020
9
33

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
364
33

Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
Kirsten Thiele, Matthias Rau, Niels-Ulrik K Hartmann, Julia Möllmann, Joachim Jankowski, Michael Böhm, András P Keszei, Nikolaus Marx, Michael Lehrke. Diabetes Obes Metab 2021
9
33


Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension.
Giovanna Castoldi, Raffaella Carletti, Silvia Ippolito, Massimiliano Colzani, Francesca Barzaghi, Andrea Stella, Gianpaolo Zerbini, Gianluca Perseghin, Cira R T di Gioia. Am J Nephrol 2020
20
33

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.
Jens Aberle, Markus Menzen, Sebastian M Schmid, Christoph Terkamp, Elmar Jaeckel, Katja Rohwedder, Markus F Scheerer, John Xu, Weifeng Tang, Andreas L Birkenfeld. Sci Rep 2020
14
33

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Glenn M Chertow, Priya Vart, Niels Jongs, Robert D Toto, Jose Luis Gorriz, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström,[...]. J Am Soc Nephrol 2021
32
33

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Paola Fioretto, Stefano Del Prato, John B Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C David Sjöström, Peter Sartipy. Diabetes Obes Metab 2018
83
33

Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Yake Lou, Ying Yu, Junchao Duan, Sining Bi, Khaing Nyein Chan Swe, Ziwei Xi, Yanan Gao, Yujie Zhou, Xiaomin Nie, Wei Liu. Ther Adv Chronic Dis 2020
4
33

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
Eva M Boorsma, Joost C Beusekamp, Jozine M Ter Maaten, Sylwia M Figarska, A H Jan Danser, Dirk J van Veldhuisen, Peter van der Meer, Hiddo J L Heerspink, Kevin Damman, Adriaan A Voors. Eur J Heart Fail 2021
38
33

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
827
33

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, Giorgia Beatrice, Kathleen E Corey, Tracey G Simon, Christopher D Byrne, Giovanni Targher. Lancet Gastroenterol Hepatol 2021
63
33

Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.
Robert D Toto, Ronald Goldenberg, Glenn M Chertow, Valerie Cain, Bergur V Stefánsson, C David Sjöström, Peter Sartipy. J Diabetes Complications 2019
15
33

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
302
33

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
277
33

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
Anne Zanchi, Michel Burnier, Marie-Eve Muller, Arlène Ghajarzadeh-Wurzner, Marc Maillard, Nicolas Loncle, Bastien Milani, Nathalie Dufour, Olivier Bonny, Menno Pruijm. J Am Heart Assoc 2020
28
33

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
Juan Antonio Requena-Ibáñez, Carlos G Santos-Gallego, Anderly Rodriguez-Cordero, Ariana P Vargas-Delgado, Donna Mancini, Samantha Sartori, Farah Atallah-Lajam, Chiara Giannarelli, Frank Macaluso, Anuradha Lala,[...]. JACC Heart Fail 2021
55
33


Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants.
Rudolph Schutte, Lutgarde Thijs, Kei Asayama, José Boggia, Yan Li, Tine W Hansen, Yan-Ping Liu, Masahiro Kikuya, Kristina Björklund-Bodegård, Takayoshi Ohkubo,[...]. Am J Hypertens 2013
24
33

SGLT2 inhibitors: β blockers for the kidney?
Richard E Gilbert. Lancet Diabetes Endocrinol 2016
28
33


SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee,[...]. Nat Commun 2020
144
33


Renin-angiotensin system: Basic and clinical aspects-A general perspective.
Rafael Antonio Vargas Vargas, Jesús María Varela Millán, Esperanza Fajardo Bonilla. Endocrinol Diabetes Nutr 2022
8
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.